MEK1 mutations confer resistance to MEK and B-RAF inhibition

Genetic alterations that activate the mitogen-activated protein kinase (MAP kinase) pathway occur commonly in cancer. For example, the majority of melanomas harbor mutations in the BRAF oncogene, which are predicted to confer enhanced sensitivity to pharmacologic MAP kinase inhibition (e.g., RAF or...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Emery, Caroline M., Vijayendran, Krishna G., Zipser, Marie C., Sawyer, Allison M., Niu, Lili, Kim, Jessica J., Hatton, Charles, Chopra, Rajiv, Oberholzer, Patrick A., Karpova, Maria B., MacConaill, Laura E., Zhang, Jianming, Gray, Nathanael S., Sellers, William R., Dummer, Reinhard, Garraway, Levi A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: National Academy of Sciences 2009
Konular:
Biological Sciences
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2777185/
https://ncbi.nlm.nih.gov/pubmed/19915144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0905833106
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller